review on glp-1 agonists and psychiatric effects The Impact of Receptor (GLP-1 RAs) Mental Health: A Systematic | Current Treatment Options in Psychiatry Psychiatric effects of GLP‐1 receptor

Potential eligibility considerations may include: BMI thresholds: Adults with BMI 30 kg/m or 27.5 kg/m for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background (adjusted thresholds reflect higher metabolic risk at lower BMI in certain ethnic groups) Previous weight management attempts: Evidence of engagement with dietary modification, increased physical activity, and behavioural interventions through a specialist weight management service Absence of contraindications: Specific contraindications will be defined in the Summary of Product Characteristics (SmPC) if the medicine is authorised Commitment to lifestyle modification: Willingness to participate in a comprehensive weight management programme Clinical trials have typically excluded individuals with recent cardiovascular events, severe renal or hepatic impairment, pregnancy or planned pregnancy, and those with a history of pancreatitis

GLP-1s naturally reduce food intake and curb cravings, making weight loss more sustainable without extreme dieting

Yes, you will gain weight after stopping GLP-1

Weight Loss Effectiveness The clinical data shows a clear effectiveness advantage for semaglutide